髋关节内注射皮质类固醇后快速破坏性髋关节病
本研究通过病例对照和回顾性队列分析,发现髋关节内注射皮质类固醇与快速破坏性髋关节病(RDHD)相关(调整OR 8.56,95%CI 3.29-22.3,P<0.0001),且存在剂量反应关系。注射后RDHD发生率为5.4%(37/688),平均诊断时间5.1个月,表现为快速进展的关节间隙狭窄、骨溶解和股骨头塌陷。单次低剂量(≤40 mg)曲安奈德注射风险低,高剂量(≥80 mg)和多次注射风险更高。
要点
- 髋关节内皮质类固醇注射与RDHD显著相关,调整OR为8.56。
- 注射后RDHD发生率为5.4%,平均诊断时间5.1个月。
- 高剂量(≥80 mg)和多次注射增加RDHD风险,应谨慎使用。
核心结论
- 髋关节内皮质类固醇注射与快速破坏性髋关节病(RDHD)相关,风险随剂量和注射次数增加。
研究设计与样本
- 第一部分为病例对照分析,病例为2013-2016年发生RDHD的患者,对照为同期因非RDHD诊断行全髋关节置换术的患者。
- 第二部分为回顾性队列分析,纳入2013-2016年在本机构接受透视引导下髋关节内皮质类固醇注射的所有患者。
主要发现
- 病例对照分析中,髋关节皮质类固醇注射与RDHD发展相关(调整OR 8.56,95%CI 3.29-22.3,P<0.0001)。
- 存在剂量反应曲线证据,RDHD风险随注射剂量和注射次数增加而增加。
- 回顾性队列分析中,注射后RDHD发生率为5.4%(37/688)。
- 注射后RDHD病例平均在注射后5.1个月被诊断,特征为快速进展的关节间隙狭窄、骨溶解和股骨头塌陷。
关键数值与推荐
- 单次低剂量(≤40 mg)曲安奈德注射后RDHD风险低。
- 高剂量(≥80 mg)注射和多次注射后RDHD风险更高。
- 应谨慎使用≥80 mg皮质类固醇的髋关节内注射和多次注射。
临床怎么用
- 为患者咨询髋关节内皮质类固醇注射相关风险提供依据。
- 避免使用≥80 mg皮质类固醇进行髋关节内注射,并避免多次注射。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While recent reports have suggested that hip corticosteroid injections can hasten joint degeneration, there are few published data on the topic. The purpose of the present study was to evaluate for an association between corticosteroid injection and rapidly destructive hip disease (RDHD) and to determine the rate of, and risk factors for, occurrence. METHODS: This study was conducted in 2 parts. First, to assess for a potential association between hip corticosteroid injection and RDHD, a case-control analysis was performed. Patients who developed RDHD between 2013 and 2016 served as cases, whereas those who underwent total hip arthroplasty for diagnoses other than RDHD during the same period served as controls, and the exposure of interest was prior intra-articular hip corticosteroid injection. Second, in a retrospective cohort analysis, we analyzed all patients who received a fluoroscopically guided intra-articular hip corticosteroid injection at our institution from 2013 to 2016. The rate of post-injection RDHD was determined, and logistic regression was used to identify risk factors for occurrence. RESULTS: In the case-control analysis, hip corticosteroid injection was associated with the development of RDHD (adjusted odds ratio, 8.56 [95% confidence interval, 3.29 to 22.3], p < 0.0001). There was evidence of a dose-response curve, with the risk of RDHD increasing with injection dosage as well as with the number of injections received. In the retrospective cohort analysis, the rate of post-injection RDHD was 5.4% (37 of 688). Cases of post-injection RDHD were diagnosed at an average of 5.1 months following injection and were characterized by rapidly progressive joint-space narrowing, osteolysis, and collapse of the femoral head. CONCLUSIONS: This study documents an association between hip corticosteroid injection and RDHD. While the risk of RDHD following a single low-dose (≤40 mg) triamcinolone injection is low, the risk is higher following high-dose (≥80 mg) injection and multiple injections. These findings provide information that can be used to counsel patients about the risks associated with this common procedure. In addition, caution should be taken with intra-articular hip injections utilizing ≥80 mg of corticosteroid and multiple injections. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Okike K, King RK, Merchant JC, et al. Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip. J Bone Joint Surg Am. 2021. PMID: 34550909. doi:10.2106/JBJS.20.02155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。